Pulse Journal Club Trending Explore Questions Researchers

Download the App

Join discussions, follow papers, and never miss your next session.

© Synapse Social LLC, 2026Privacy Policy

Home Explore Journal Club Trending

⌘+K

What’s next for psychedelics after MDMA rejection? | Synapse

August 15, 2024

What’s next for psychedelics after MDMA rejection?

Key Points

Key points are not available for this paper at this time.

Abstract

Lykos's failure to win FDA approval for PTSD therapy may accelerate a strategic shift among its competitors.

Mark Helpful

Bookmark

Relay

Cite This Study

Kai Kupferschmidt (Thu,) studied this question.

synapsesocial.com/papers/68e5c0f4b6db643587558db5 https://doi.org/https://doi.org/10.1126/science.ads4470

Mark Helpful

Bookmark

Relay

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Psychedelics field looks ahead after FDA advisers’ rejection2024 · 3 citations
2Lykos cuts workforce, revamps in wake of FDA decision2024
3Psychedelics’ Use as Medicine Hits Significant Roadblock2024
4FDA advisory committee rejects MDMA application for PTSD, but…2024
5FDA publicly releases MDMA rejection letter; MAPS vows to press forward2025